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Background: The purpose of the present study was to evaluate the effect and predictive value of metabolic
syndrome (MetS) and its components on diastolic heart failure (DHF) in patients at high risk for coronary artery
disease (CAD).
Materials and methods: We enrolled 261 patients with normal left ventricular ejection fraction (≥50%) who were
scheduled to undergo coronary angiography for suspected myocardial ischemia. They were categorized into three
groups (non-MetS, pre-MetS and MetS) based on the number of MetS criteria. Echocardiography was used to assess
left ventricular (LV) diastolic function. The association between MetS and DHF was assessed by multivariate logistic
regression (MLR) analysis (non-DHF patients as reference group) after controlling for confounders. The predictive
performance of the MetS severity score (MSS) was evaluated using the area under the receiver-operating
characteristic curve (AUC).
Results: A tendency toward increased DHF prevalence with increasing MSS was found (p < 0.001). MLR analysis
showed that in patients with an MSS of 1, the odds ratio (OR) of DHF was 1.60 (95% confidence interval-CI,
1.19–2.16; p = 0.02) compared to non-DHF patients; in patients with MSS ≥4, the OR was 6.61 (95% CI, 4.90–8.90;
p < 0.001) compared to non-DHF patients. MSSs strongly predicted DHF (AUC = 0.73, 95% CI, 0.66–0.78, p < 0.001).
MLR with MetS components as binary variables showed that blood pressure (BP) and triglycerides (TGs) were
significantly associated with DHF (P = 0.001 and 0.043, respectively).
Conclusion: Our findings signify that MetS and its components of BP or TG were associated with DHF in high-risk
CAD patients. DHF prevalence tends to increase with increasing MSS that has a high value in predicting DHF in
high-risk CAD patients.
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Metabolic syndrome (MetS) is a global health concern
and refers to a constellation of the risk factors of cardio-
vascular disease, including obesity, abdominal fat distri-
bution, disorders of glucose and lipid metabolism and
hypertension (HT) [1]. The burden of MetS is likely to
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reproduction in any medium, provided the oractivity and increase in obesity in our society [2]. Dia-
stolic heart failure (DHF) refers to a decline in the per-
formance of one or both ventricles of the heart during
diastole and is characterized by elevated diastolic pres-
sure in the left ventricle (LV), despite an essentially nor-
mal end-diastolic volume [2]. Studies have suggested
that the morbidity and mortality of DHF are similar to
those of systolic heart failure [3,4]. DHF is a powerful
and independent predictor of death [5]. DHF can be
attributed to multiple factors that are mainly linked
to metabolic disturbances [4,5]. Some components of
MetS– such as hypertension and fasting blood glucose
are strongly associated with DHF, which leads tod. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[4,5]. Moreover, hypertension, diabetes mellitus (DM)
and obesity have been found to adversely affect cardiac
structure and function [6,7].
Patients who are at a high risk for coronary artery dis-
ease (CAD) characteristically have HT, DM and hyper-
lipidemia. MetS and DHF tend to be co-prevalent in
high-risk CAD patients, who account for more than half
of the patients hospitalized in departments of cardiovas-
cular disease [8]. High-risk CAD patients with DHF have
been found to have high morbidity and mortality. It is
important to clarify the relationship between MetS and
DHF in high-risk CAD patients, as this information can
be of benefit to clinicians in the prediction, prevention
and treatment of DHF. However, the extent to which the
clustering of MetS components predicts DHF in high-
risk CAD patients is unknown. In addition, the effects of
MetS and its components on DHF have not been well
characterized in this subgroup of patients. The purpose
of the present study was to evaluate the effect and pre-




Two hundred and sixty-one consecutive symptomatic or
asymptomatic Chinese patients who had normal LV
ejection fraction (LVEF; ≥50%) and were scheduled to
undergo coronary angiography for suspected myocardial
ischemia were recruited between February 2009 and
March 2011 at the Huashan Hospital of Fudan Univer-
sity, China. Patients were excluded from the study to
eliminate potential confounding factors that may have
influenced heart function. The exclusion criteria were as
follows: (1) history or findings of systolic heart failure
(LVEF ≤ 45%), significant valvular heart disease (i.e.,
more than a mild valvular insufficiency or stenosis),
hyperthyroidism or hypothyroidism and dilated or hy-
pertrophic cardiomyopathy, (2) pregnancy or lactation
and/or (3) a major systemic illness, such as systemic
lupus erythematosus. Written consent was obtained
from all patients before the study, which was performed
in accordance with the ethical standards laid down in
Declaration of Helsinki and approved by the Medicine
Ethical Committee of Fudan University.
MetS was diagnosed according to the updated Na-
tional Cholesterol Education Program/Adult Treatment
Panel III criteria (WHO Western Pacific Region obesity
criteria) in individuals meeting three or more of the fol-
lowing [9]: (1) central obesity, defined using ethnicity-
specific values as a waist circumference (WC) of ≥90 cm
in men or ≥80 cm in women; (2) raised triglyceride (TG)
levels, >150 mg/dl (1.7 mmol/l) or specific treatment
for this lipid abnormality; (3) reduced high-densitylipoprotein (HDL) cholesterol, <40 mg/dl (1.03 mmol/l)
in men and <50 mg/dl (1.29 mmol/l) in women or spe-
cific treatment for this lipid abnormality; (4) raised
blood pressure (BP), systolic BP >130 mm Hg or dia-
stolic BP >85 mm Hg or treatment for previously diag-
nosed HT; and (5) raised fasting plasma glucose (FPG)
level, >100 mg/dl (>5.6 mmol/l) or previously diagnosed
type 2 DM. Patients with raised FPG levels were
strongly recommended to undergo an oral glucose-
tolerance test. In addition, if the body mass index (BMI)
was >30 kg/m2, central obesity was assumed, and WC did
not need to be measured. For analysis, the study subjects
were grouped according to the number of MetS criteria
they satisfied: non-MetS (0 criteria), pre-MetS (1–2 cri-
teria) and MetS (≥3 criteria). MetS severity was scored on
a scale of 0 to 4 according to the number of MetS compo-
nents present. Three subjects met all five MetS criteria,
and their MetS severity score (MSS) was set to 4.
The subjects were interviewed for the documentation
of medical histories, medications, history of smoking
habits, laboratory assessment of cardiovascular disease
risk factors and standardized echocardiographic exami-
nation. BMI was calculated as the weight in kilograms
divided by the square of height in meters. SBP and DBP
values were the means of two physician-obtained mea-
surements on the left arm of the seated participant. HT
was diagnosed if the BP was ≥140/90 mm Hg and/or the
patient was undergoing antihypertensive therapy. DM
was diagnosed on the basis of the oral glucose tolerance
test and either a glycosylated hemoglobin (HbAlc) level
of ≥6.5% or the use of insulin or hypoglycemic medica-
tions. CAD was diagnosed if any one of the following
were present: (1) history and/or treatment for angina
and/or myocardial infarction; (2) history of coronary ar-
tery revascularization procedures and/or coronary angi-
ography with ≥50% stenosis in one or more of the major
coronary arteries; and (3) regional wall-motion abnor-
malities on rest echocardiography.
Laboratory assays
Peripheral venous blood samples were collected in tubes
in the fasting state in all subjects. The blood was
centrifuged at 3000 rpm for 10 min for plasma separ-
ation and immediately used to measure biomarkers. FPG
was measured using the glucose oxidase procedure;
HbA1c was measured using ion-exchange high-perform-
ance liquid chromatography (HPLC; Bio-Rad, Hercules,
CA, USA). Serum total cholesterol (TC), HDL choles-
terol, TGs, creatinine (Cr) and uric acid (UA) levels were
measured using an enzymatic method with a chemical
analyzer (Hitachi 7600–020, Tokyo, Japan). Low-density
lipoprotein (LDL) cholesterol levels were calculated
using the Friedewald formula, and the creatinine clear-
ance rate (Ccr) was calculated using the Cockcroft-Gault
Tang et al. Diabetology & Metabolic Syndrome 2013, 5:30 Page 3 of 8
http://www.dmsjournal.com/content/5/1/30formula. The day-to-day and inter-assay coefficients of
variation at the central laboratory in our hospital for all
analyses were between 1% and 3%.
Echocardiographic measurement
Echocardiography examinations were performed with a
Vingmed System 5 Doppler echocardiographic unit
(GE Vingmed Ultrasound, Horten, Norway). Conven-
tional echocardiography measurements were performed
according to American Society of Echocardiography
guidelines. LV mass (LVM) was calculated using the
Devereux formula. The LVM was corrected for body
surface area (BSA) to obtain the LVM index (LVMI).
The left atrial diameter (LAD) and aortic root dimension
(AOD) were also measured. LV systolic function was
assessed using the LVEF. Diastolic function was assessed
by determining the E-to-A ratio (E/A) and deceleration
time (DT), where E and A represent the early and late
ventricular filling velocities, respectively.
We used the definition of DHF recommended in the
European Society of Cardiology guidelines in 2008 [10].
The diagnosis of DHF required the following three
conditions: (1) presence of signs and/or symptoms of
chronic heart failure meanly involved in shortness of
breath, rapid heartbeat, wheezing or abnormal heart
sounds and swollen legs; (2) presence of normal or only
mildly abnormal LV systolic function (LVEF, 45%–50%);
and (3) evidence of diastolic dysfunction (abnormal LV
relaxation or diastolic stiffness). Diastolic function of the
LV was evaluated on the basis of the ventricular filling
pattern in patients with heart failure. Normal LV dia-
stolic function was defined as an E/A ratio >1 and
160 ms < DT < 240 ms. LV diastolic dysfunction was
defined as (1) E/A ratio <1 and DT ≥260 ms or (2) E/A
ratio >2 and DT <150 ms.
Statistical analysis
The Kolmogorov-Smirnov test was used to determine
whether continuous variables followed a normal distri-
bution. Variables that were not normally distributed
were log-transformed to approximate normal distribu-
tion for analysis. The results are expressed as the mean ±
SD or median, unless otherwise stated. The characteris-
tics of the subjects according to MetS groups were
assessed using one-way analysis of variance (ANOVA)
for continuous variables and the χ2 test for categorical
variables. Univariate linear regression was performed to
determine the variables associated with DHF and to es-
timate confounding factors possibly disturbing the rela-
tionship between MetS and DHF. Multivariate logistic
linear regression (MLR) was carried out to determine
the independent contributions of variables to DHF (non-
DHF patients as reference group). Potential confounding
variables, including age, gender, smoking, LAD, LVMI,UA, Ccr and Cr, were controlled in the regression model.
Variables were entered into the backward stepwise regres-
sion models if a p value of <0.10 was obtained. The models
were re-analyzed after substituting the continuous variables
related to all MetS components with their dichotomous
counterparts in the models. The predictive performance of
the MSS was evaluated using the area under the curve
(AUC) in a receiver operating characteristics (ROC) curve.
Odds ratios (ORs) with 95% confidence intervals (CIs)
were calculated for the relative risk of MetS with DHF.
The results were analyzed using the Statistical Package for
Social Sciences for Windows, version 16.0 (SPSS, Chicago,
IL, USA). The tests were two-sided, and a p value of <0.05
was considered significant.
Results
The baseline clinical characteristics of the 261 subjects
were grouped according to the type of MetS (Table 1).
The total sample included 153 men and 108 women
(mean age, 59.56 ± 14.53 years), and 24.53% of these
patients were found to have MetS. Gender, height and
TC levels were similar among the three MetS groups
(p > 0.05), while the other demographic parameters
and biochemical variables were significantly different
(p < 0.05). LVEF did not significantly differ among the
three groups, but LAD, DT and LVMI did (p < 0.05). The
prevalence of CAD, HT and DM were 30.3%, 59.4% and
39.1% in the patients, respectively. These three condi-
tions were more prevalent in the MetS group than the
other two groups (p < 0.05). Smoking habits were similar
among the three groups, while the use of oral medica-
tions was significant different (p < 0.05).
Prevalence of DHF in high-risk CAD patients
The prevalence of DHF was 52.50% in the total sample
and 20.80%, 52.3% and 76.6% in the non-MetS, pre-
MetS and MetS groups, respectively. DHF prevalence
was 71.61%, 66.37% and 69.62% in patients with HT,
DM and CAD, respectively (Figure 1). DHF prevalence
was significantly lower in patients without HT (24.76%)
than in patients with HT (p < 0.001). Similar DHF preva-
lence was found in patients with DM and without DM
(41.89%) and those with and without CAD (45.14%;
p < 0.001 for both). In addition, DHF prevalence signifi-
cantly differed with the MSS (MSS 0, 20.83%; 1, 41.77%;
2, 64.28%; 3, 71.11%; and 4, 89.47%; p < 0.01; Figure 2).
As the MSS increased, the prevalence of DHF also
increased (p for trend < 0.01; Figure 2).
MetS severity and DHF
To estimate the association of MetS severity and other
factors with DHF, univariate logistic regression models
were developed to include gender, age, height, weight,
BMI, WC, SBP, DBP, FPG, TG, HDL, other lipid profiles,
Table 1 Characteristics of the study population
Variable Total (n = 261) Non-MetS (n = 48) Pre-MetS (n = 149) MetS (n = 64) p value
Age 59.56 ± 14.53 51.27 ± 14.45 59.68 ± 14.4 65.48 ± 11.85 <0.001
Gender (male, %) 153(58.6%) 25(52.1%) 89(59.7%) 39(60.9%) 0.588
Height 165.83 ± 8.11 165.1 ± 8.45 165.95 ± 7.77 166.08 ± 8.71 0.789
Weight 65.11 ± 11.74 58.55 ± 8.49 63.63 ± 10.87 73.47 ± 11.34 <0.001
BMI 23.56 ± 3.54 21.38 ± 2.08 22.97 ± 3.29 26.55 ± 3.11 <0.001
WC 82.92 ± 7.82 77.97 ± 6.213 82 ± 7 87.04 ± 7.19 <0.001
SBP 128 ± 18 116 ± 11 128 ± 18 136 ± 18 <0.001
DBP 76 ± 11 72 ± 7 76 ± 11 81 ± 13 <0.001
HR 71 ± 11 66 ± 11 72 ± 11 73 ± 12 0.007
Laboratory assay
FPG 6.02 ± 2.52 4.83 ± 0.26 6.11 ± 2.88 6.73 ± 2.25 <0.001
PBG 8.48 ± 4.08 6.24 ± 0.83 8.4 ± 4.25 9.66 ± 4.32 0.004
HbAlc 6.74 ± 2.13 5.23 ± 0.42 6.91 ± 2.36 7.16 ± 1.97 0.003
TC 4.5 ± 1.12 4.21 ± 0.81 4.59 ± 1.13 4.49 ± 1.26 0.142
TG 1.61 ± 1.2 0.98 ± 0.33 1.49 ± 0.95 2.34 ± 1.68 <0.001
HDL 1.14 ± 0.3 1.3 ± 0.28 1.16 ± 0.3 0.99 ± 0.23 <0.001
LDL 2.56 ± 0.89 2.31 ± 0.67 2.67 ± 0.92 2.49 ± 0.91 0.048
Cr 76.11 ± 25.93 68.04 ± 14.06 74.84 ± 22.45 84.78 ± 35.96 0.002
Ccr 85.58 ± 30.31 91.04 ± 24 85.46 ± 31.27 81.95 ± 31.97 0.300
UA 0.34 ± 0.1 0.3 ± 0.08 0.34 ± 0.1 0.38 ± 0.12 0.001
Echocardiographic measurement
LVEF (%) 65 ± 6 65 ± 4 66 ± 4 65 ± 6 0.426
DT 217.29 ± 56.37 196.67 ± 43.63 214.3 ± 59.54 239.7 ± 50.12 <0.001
LAD 36.17 ± 4.81 33.67 ± 4.07 35.7 ± 4.45 39.14 ± 4.75 <0.001
LVMI 112.77 ± 35.91 98.51 ± 28.23 108.46 ± 35.72 133.71 ± 33 <0.001
DHF (yes, %) 137(52.5%) 10(20.80%) 78(52.3%) 49(76.6%) <0.001
Past medical history (yes, %)
CAD 79(30.3%) 6(12.5%) 41(27.5%) 32(50%) <0.001
HT 155(59.4%) 0(0.0%) 95(63.8%) 60(93.8%) <0.001
DM 102(39.1%) 0(0.0%) 58(38.9%) 44(68.8%) <0.001
Smoking 75(28.7%) 14(29.2%) 49(32.9%) 12(18.8%) 0.106
Medical therapy (yes, %)
Anti-hypertension 140(53.6%) 0(0.0%) 85(57%) 55(85.9%) <0.001
Hypoglycaemic 78(29.9%) 0(0.0%) 45(30.2%) 33(51.6%) <0.001
Anti-lipids 69(26.4%) 5(10.41%) 41(27.5%) 23(35.9%) 0.009
Note: BMI Body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, MetS metabolic syndrome, HT Hypertension, DM Diabetes, FPG fasting
plasma glucose, PBG plasma blood glucose, HbA1c glycated hemoglobin, TC serum total cholesterol, HDL high-density lipoprotein cholesterol, TG triglyceride,
UA uric acid, LDL low density lipoprotein cholesterol, Ccr creatinine clearance rate, Cr creatinine, LVMI left ventricular mass index, LAD left atrial diameter, DT
deceleration time, LVEF left ventricular ejection fraction.
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medical history and medical therapy (Table 2). The uni-
variate analyses indicated that age, height, Cr, Ccr, UA,
LVMI, CAD, DM, HT, MetS and all its components,
except HDL, were significantly associated with DHF
(p < 0.05 for all). MLR analysis was carried out to deter-
mine the extent to which DHF was associated with MetSseverity. MetS remained significantly associated with
DHF after adjustments for age, height, Cr, Ccr, UA,
LVMI, HT, DM and CAD (p = 0.023, data not shown). In
patients with an MSS of 1, the OR of DHF was 1.60
(95% CI, 1.19–2.16; p = 0.02; Table 3) compared to
non-DHF patients, while in patients with an MSS ≥ 4,
the OR was 6.61 (95% CI, 4.90–8.90; p < 0.001)
Figure 1 Prevalence of diastolic heart failure (DHF) in patients
with hypertension (HT), diabetes mellitus (DM) and coronary
artery disease (CAD).
Table 2 Univariate regression analysis for diastolic heart
failure
Variables β S.E. P value OR 95.0% C.I.
BMI 0.60 0.27 0.03 1.82 1.06-3.14
SBP 0.05 0.01 <0.001 1.06 1.04-1.08
DBP 0.03 0.01 0.003 1.03 1.01-1.06
FPG 0.83 0.50 0.010 2.29 1.85-6.17
TG 0.69 0.28 0.014 2.00 1.15-3.47
HDL −0.47 0.43 0.269 0.62 0.27-1.45
MetS 0.78 0.13 <0.001 2.20 1.70-2.84
Age 0.86 0.11 <0.001 2.36 1.87-2.99
Ccr −0.02 0.01 <0.001 0.97 0.97-0.98
Cr 0.02 0.01 <0.001 1.02 1.01-1.04
UA 1.38 0.37 <0.001 4.00 1.94-8.26
LVMI 0.02 0.01 <0.001 1.02 1.02-1.03
HT 2.03 0.28 <0.001 7.66 4.36-13.48
DM 1.01 0.26 <0.001 2.73 1.65-4.55
CAD 1.02 0.28 <0.001 2.78 1.58-4.90
Note: MI Body mass index, SBP systolic blood pressure, DBP diastolic blood
pressure, MetS metabolic syndrome, HT Hypertension, DM Diabetes, FPG
fasting plasma glucose, PBG plasma blood glucose, HbA1c glycated
hemoglobin, TC serum total cholesterol, HDL high-density lipoprotein
cholesterol, TG triglyceride, UA uric acid, LDL low density lipoprotein
cholesterol, Ccr creatinine clearance rate, Cr creatinine, LVMI left ventricular
mass index, LAD left atrial diameter, DT deceleration time, LVEF left ventricular
ejection fraction.
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ive performance of MSSs for DHF, the AUC in an ROC
curve was calculated. The AUC was 0.726 (95% CI,
0.665–0.787; p < 0.001), indicating that the MSS strongly
predicted DHF (Figure 3).
MetS components and DHF
MLR analysis with the whole covariate model and back-
ward stepwise regression model with adjustments for
confounders were developed to include MetS compo-
nents as continuous variables. The enter regression
model after adjustments for age, Cr, Ccr, UA, LVMI and
CAD indicated that DBP was significantly associated
with DHF (p = 0.022; data not shown). The backward
stepwise regression model showed that age, UA, LVMI
and DBP were independently associated with DHF
(p = 0.001, 0.041, 0.044 and 0.001, respectively; data not
shown). To reduce the effect of medical therapy, MLR
models with adjustments for confounders were devel-
oped to include MetS components as binary variables.Figure 2 Prevalence of diastolic heart failure (DHF) according
to metabolic syndrome (MetS) severity score.The results showed that BP and TG were significantly
associated with DHF (p = 0.001 and 0.043, respectively in
the enter regression model; p = 0.001 and 0.038, respect-
ively in the backward stepwise regression model; Table 4).
Discussion
We first conducted a case–control study to evaluate the
effect of metabolic factors on DHF in Chinese high-risk
CAD patients. CAD, HT and DM were more prevalent
in patients with MetS. Most of the demographic factors,
biochemical characteristics and echocardiographic mea-
surements significantly differed among the three MetS
groups. Doppler echocardiography has become a well
accepted, reliable, noninvasive tool to measure theTable 3 Multiple logistic regression analysis for diastolic
heart failure, including metabolic syndrome (MetS)
MetS severity score Number β P value OR 95% CI
0 (reference) 48 0.0 — 1.00 —
1 79 0.47 0.020 1.60 1.19-2.16
2 70 0.94 <0.001 2.57 1.91-3.46
3 45 1.42 <0.001 4.12 3.06-5.55
≥ 4 19 1.88 <0.001 6.61 4.90-8.90
Note: Adjusted for age, gender, serum creatinine, creatinine clearance rate,
serum uric acid, left ventricular mass index and coronary artery disease.
Figure 3 Receiver operative characteristic (ROC) curve showing
the performance of metabolic syndrome (MetS) severity score
in predicting the prevalence of diastolic heart failure (DHF).
Area under the curve (AUC) = 0.726, (95% confidence interval,
0.665–0.787), p < 0.001.
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echocardiography was used to measure LV diastolic
function in order to diagnose DHF.
The main finding of the present study was that MetS
strongly and independently predicted DHF in high-risk
CAD patients. The prevalence of DHF increased with
the severity of MetS. HT, insulin resistance and obesity
have been associated with LV diastolic dysfunction or
DHF in different populations [11,12]. In addition, MetS
has been independently correlated with DHF in differentTable 4 Multiple logistic regression analysis for diastolic
heart failure (DHF) and components of metabolic
syndrome (MetS) as binary variables
Model Variable β S.E. P value OR 95% CI
Model 1 BMI 0.12 0.407 0.773 1.125 0.51-2.5
BP 1.82 0.428 <0.001 6.197 2.68-14.35
FBG 0.47 0.364 0.201 1.592 0.78-3.25
TG 0.80 0.416 0.043 2.236 1.01-5.05
HDL −0.36 0.376 0.339 0.698 0.33-1.46
Model 2 Constant −3.41 0.514 <0.001
Age 0.69 0.146 <0.001 2.004 1.51-2.67
UA 0.93 0.488 0.045 2.546 1.08-6.62
BP 1.93 0.413 <0.001 6.893 3.07-15.49
TG 0.81 0.388 0.038 2.236 1.05-4.78
Note: Model 1 adjusted for age, serum creatinine, creatinine clearance rate,
serum uric acid, left ventricular mass index and coronary artery disease; Model
2 was the best model. The following variables were entered in step 1: age,
serum creatinine, creatinine clearance rate, serum uric acid, left ventricular
mass index and coronary artery disease, body mass index, blood pressure,
fasting blood glucose, triglycerides and high-density lipoprotein.
SE standard error, OR odds ratio, CI confidence interval.subgroups such diabetic, non-diabetic or hypertensive
patients [13-15]. In the present study, the association be-
tween MetS and DHF was observed in both the univari-
ate and multivariate models after adjustment for
potential confounders in high-risk CAD patients. Specif-
ically, we found a good association between the MSSs
and DHF. To our knowledge, this is the first study to
have reported such an association in a population of
high-risk CAD patients. In the multivariate analysis,
MetS was independently associated with DHF, even after
adjustment for potential confounders such as parameters
of renal function, LVMI and CAD. This finding is of spe-
cial importance if the direct relationship between MetS
and DHF is considered. The clustering of cardiovascular
risk factors in MetS indicates that the multiple complex
metabolic reactions involved in glycotoxicity, lipotoxi-
city, altered insulin signaling, increased cytokine activity
and interstitial deposition of triacylglycerol may directly
or indirectly impact myocardial function [4,16-20].
Additionally, these metabolic risk factors lead to reduced
energy availability, and have an additive, adverse effect
on endothelial function [21].
In the present study, the AUC was calculated to show
that the MSS strongly predicts DHF. In patients with
MSSs of up to 4, the prevalence of DHF was nearly 90%.
This finding indicates that the severity of MetS is linked
to the progression of DHF. This is one of interesting
findings of the present study, which not only supports
further studies on the mechanism of DHF but also pro-
vides evidence for clinicians to predict DHF in hospital-
ized patients. However, in the present study, we scored
the MetS severity by simply using the number of MetS
criteria. We did not consider the weights of the MetS
components. For instance, the BP component of MetS
makes a greater contribution to DHF. A large-scale, case–
control study or cohort study with a better method of
scoring MetS severity will be conducted to develop a
highly sensitive and specific model that uses MetS infor-
mation to predict DHF. Such a model would facilitate the
prevention and treatment of DHF in clinical practice.
Another interesting finding of the present study was
that BP and TG were the only MetS components that
contributed to DHF. This finding is inconsistent with
those of some earlier studies, which had revealed that
BMI, SBP, DBP and lipid profiles were significantly asso-
ciated with diastolic parameters and the structure and
functions of the LV [4,16-18,20]. In the present study,
BMI, FPG and HDL were not significantly associated
with DHF. This difference is partly because the contri-
butions of individual MetS components could not be
detected in the present study, which had a moderate
sample size. Another possible cause is that the present
study population differed from those in previous studies;
we performed association analysis for MetS and DHF
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hyperlipidemia, which were potential confounders of
DHF. In addition, MetS components as continuous vari-
ables may not reflect the true values in patients under-
going medical therapy. For example, the FPG values
measured in the present study were less than the true
values in DM patients using hypoglycemic drugs.
However, we focused on metabolic factors associated
with DHF in a specific subgroup, high-risk CAD pa-
tients. Our findings will provide evidence for clini-
cians to better understand and treat patients in this
specific subgroup. Nevertheless, further studies should
explore the effects of MetS on DHF in an exclusive
subgroup such as patients with CAD or hyperlipid-
emia. DBP as a continuous variable was found to be
associated with DHF in both the univariate and
multivariate models. The results were confirmed in
the MLR analysis with BP as a binary variable. DBP
has been found to be an important predictor of LV
diastolic dysfunction or DHF [20,22]. DBP can dir-
ectly influence diastolic function and remodel the LV
structure, leading to DHF [23]. In the present study,
TG as a binary variable was associated with DHF in
both the univariate and multivariate analyses. Other
studies have reported similar results [11,24]. No con-
sistent results have been found in MLR analyses with
TG as a continuous variable. This is partly because
high-risk CAD patients were regularly treated with
anti-lipids drugs such as statins to prevent events of
cardiovascular disease; this may have influenced the
true value of TG, making it difficult to determine the
effect of TG on DHF. The exact mechanism under-
lying the association between TG and DHF has not
been fully elucidated. In the present study, we did
not determine the mechanism via which TG modifies
metabolic factors and induces DHF.
Several limitations of the study deserve comment.
First, the design of the present study was hospital-
based, which is susceptible to selection bias. Second,
the sample size was moderate, limiting its ability to
detect significant results. Third, the multiple regres-
sion models indicated only a moderate influence of
MetS on DHF. Other environmental and genetic fac-
tors may contribute to the unexplained variation in
DHF prevalence. Fourth, the association between in-
sulin resistance and DHF was not analyzed in the
present study. This is because data on fasting blood
insulin levels were missing. Furthermore, most of par-
ticipants were enrolled with the first diagnosis of dia-
stolic heart failure or not. So we did not collect
information of the history of diastolic heart failure.
Finally, it is important to mention that our study was
performed on Chinese individuals, and our findings
may not be relevant to people of other ethnicities.Conclusion
In conclusion, individuals with MetS frequently have a
higher prevalence of DHF. Our findings signify that
MetS is an independent predictor of DHF, and BP and
TG, as components of MetS, are independently associ-
ated with DHF. There is a tendency toward increased
prevalence of DHF with increasing MSSs. This supports
the hypothesis that MetS is involved in the regulation of
DHF progression. The present observations provide evi-
dence that improved metabolic control may coordinately
and perhaps even synergistically inhibit the progression
of DHF and also provide novel insights into biological
functions, in the future.
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